Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies: a Randomized, Double Blind, Phase III Study Versus Allopurinol

Trial Profile

Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies: a Randomized, Double Blind, Phase III Study Versus Allopurinol

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jul 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Febuxostat (Primary) ; Allopurinol
  • Indications Haematological malignancies; Tumour lysis syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms FLORENCE
  • Sponsors Menarini
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 27 Jul 2015 Results published in the Annals of Oncology.
    • 30 Jun 2015 According to a Teijin Pharma media release, Menarini has received approval for febuxostat [Adenuric] in Europe for an expanded indication of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of tumor lysis syndrome. The approval is based on positive results from this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top